South Africa’s vaccine regulator has reached new WHO level to ensure safety, quality, and effectiveness.
According to World Health Organization’s (WHO’s) global classification system for national medical product regulatory authorities, WHO has ranked South Africa’s vaccine regulatory system at a functional level of maturity. This ranking recognizes that South Africa has a stable, well-functioning, and integrated regulatory system to ensure the quality, safety, and effectiveness of vaccines manufactured, imported, or distributed in the country.
WHO confirmed that the country has attained maturity level three (ML3), the third of four levels in WHO’s classification system. Maturity level four (ML4) is the highest.
“This achievement affirms South Africa’s trailblazing endeavor in health research. Beyond its technical aspects, this milestone carries real implications for people’s health. We cannot talk about better health care without quality medical supplies,” said Matshidiso Moeti, WHO regional director for Africa, in a press release. “This is an important new step not only for South Africa, but for the region, toward self-sufficiency in vaccines and medicines.”
“This rapid progress on vaccines regulation is a significant milestone for South Africa, the Southern African region, and the continent. It is an important win for vaccine equity, as the country is a major manufacturer of medical products, and this regulatory milestone will help maximize the impact of the mRNA [messenger RNA] vaccine technology hub,” said Tedros Adhanom Ghebreyesus, WHO director-general, in the release.
Source: WHO
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.